Avastin success in Ovarian Cancer trial
Avastin (bevacizumab) from Genentech/Roche, in a trial led by Timothy Perren, from Leeds Teaching Hospitals NHS Trust, improved overall survival (OS) in women with high-risk advanced Ovarian Cancer. Data presented at the ESMO conference 2013 showed that women at highest risk of their cancer recurring who were given Avastin in combination with chemotherapy, and then continued maintenance Avastin, and lived on average 9.4 months longer than those on chemotherapy alone (median OS 39.7 months vs. 30.3 months).
The ESMO conference also heard that women who received Avastin were less likely to relapse within 12 months of the start of the trial compared to a control group who received standard chemotherapy.
150 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.